WANY
VTYX

Wealthspire Advisors (New York)’s Ventyx Biosciences VTYX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-844
Closed -$2.63K – 2867
2025
Q3 		$2.63K Buy
+844
New +$2.24K ﹤0.01% 2531

Other funds holding VTYX

AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wealthspire Advisors (New York)'s VTYX Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Ventyx Biosciences (VTYX) in Q4 2025, closing a stake of 844 shares — an estimated $2.63K sold.

Wealthspire Advisors (New York) first reported a position in VTYX in Q3 2025 and held it in 1 quarter. The position peaked at $2.63K in Q3 2025. 139 funds tracked by Wall St. Rank hold VTYX as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Ventyx Biosciences position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 844 Ventyx Biosciences shares in Q4 2025, an estimated $2.63K.
  • Wealthspire Advisors (New York) first reported a position in Ventyx Biosciences in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Ventyx Biosciences position peaked at $2.63K in Q3 2025.
  • 139 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.